NPS seeks FDA nod for hypoparathyroidism drug Natpara
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals is seeking the US FDA's approval to market Natpara (recombinant human parathyroid hormone 1-84, rhPTH[1-84]) as a treatment for hypoparathyroidism, a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone (PTH), a principal regulatory of the body’s mineral homeostasis.